index,title,abstract,Master Ref#,PubMed ID,Journal,Primary Author,Publication Year,Volume / Issue,Pages,Priority Journal,PubMed ID:,Full Reference:,"Study Outcome ($/QALY, $/DALY, Both):",Study Country:,Disease Classification:,Intervention Type(s):,Intervention Phrase vs. Comparator Phrase:,Target Characteristics:,Max Target Age:,Min Target Age:,Target Genders:,Review:,Time Horizon:,Discounting Rate (Costs):,Discounting Rate (QALYs):,Incremental Cost-Effectiveness Ratio (Original currency and year):,Currency Country:,Currency Year:,Incremental Cost-Effectiveness Ratio (Converted to current $USD):
32501,Empagliflozin in combination therapy for treating type 2 diabetes,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2015-01-41595,,NotApplicable,NotApplicable,2015,NotApplicable /,,No,Not Stated,"NotApplicable; Empagliflozin in combination therapy for treating type 2 diabetes, NotApplicable, ; NotApplicable():",QALY,"England, Wales",Diabetes mellitus,Pharmaceutical,canagliflozin vs. empagliflozin 25 mg,Not Stated,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.50,3.50,-4600,United Kingdom,2012,-8606.7
32502,Empagliflozin in combination therapy for treating type 2 diabetes,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2015-01-41595,,NotApplicable,NotApplicable,2015,NotApplicable /,,No,Not Stated,"NotApplicable; Empagliflozin in combination therapy for treating type 2 diabetes, NotApplicable, ; NotApplicable():",QALY,"England, Wales",Diabetes mellitus,Pharmaceutical,empagliflozin vs. empagliflozin,Not Stated,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.50,3.50,-7062.5,United Kingdom,2012,-13214.09
32503,Empagliflozin in combination therapy for treating type 2 diabetes,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2015-01-41595,,NotApplicable,NotApplicable,2015,NotApplicable /,,No,Not Stated,"NotApplicable; Empagliflozin in combination therapy for treating type 2 diabetes, NotApplicable, ; NotApplicable():",QALY,"England, Wales",Diabetes mellitus,Pharmaceutical,sitagliptin vs. empagliflozin,Not Stated,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.50,3.50,-2531.25,United Kingdom,2012,-4736.02
32504,Empagliflozin in combination therapy for treating type 2 diabetes,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2015-01-41595,,NotApplicable,NotApplicable,2015,NotApplicable /,,No,Not Stated,"NotApplicable; Empagliflozin in combination therapy for treating type 2 diabetes, NotApplicable, ; NotApplicable():",QALY,"England, Wales",Diabetes mellitus,Pharmaceutical,canagliflozin vs. empagliflozin,Not Stated,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.50,3.50,-75400,United Kingdom,2012,-141075.03
32505,Empagliflozin in combination therapy for treating type 2 diabetes,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2015-01-41595,,NotApplicable,NotApplicable,2015,NotApplicable /,,No,Not Stated,"NotApplicable; Empagliflozin in combination therapy for treating type 2 diabetes, NotApplicable, ; NotApplicable():",QALY,"England, Wales",Diabetes mellitus,Pharmaceutical,empagliflozin vs. empagliflozin,Not Stated,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.50,3.50,9571,United Kingdom,2012,17907.55
32506,Empagliflozin in combination therapy for treating type 2 diabetes,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2015-01-41595,,NotApplicable,NotApplicable,2015,NotApplicable /,,No,Not Stated,"NotApplicable; Empagliflozin in combination therapy for treating type 2 diabetes, NotApplicable, ; NotApplicable():",QALY,"England, Wales",Diabetes mellitus,Pharmaceutical,Canagliflozin vs. Empagliflozin,Not Stated,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.50,3.50,-8000,United Kingdom,2012,-14968.17
32507,Empagliflozin in combination therapy for treating type 2 diabetes,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2015-01-41595,,NotApplicable,NotApplicable,2015,NotApplicable /,,No,Not Stated,"NotApplicable; Empagliflozin in combination therapy for treating type 2 diabetes, NotApplicable, ; NotApplicable():",QALY,"England, Wales",Diabetes mellitus,Pharmaceutical,canagliflozin vs. empagliflozin,Not Stated,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.50,3.50,4933,United Kingdom,2012,9229.75
32508,Empagliflozin in combination therapy for treating type 2 diabetes,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2015-01-41595,,NotApplicable,NotApplicable,2015,NotApplicable /,,No,Not Stated,"NotApplicable; Empagliflozin in combination therapy for treating type 2 diabetes, NotApplicable, ; NotApplicable():",QALY,"England, Wales",Diabetes mellitus,Pharmaceutical,sitagliptin vs. canagliflozin,Not Stated,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.50,3.50,-2600,United Kingdom,2012,-4864.66
32509,Empagliflozin in combination therapy for treating type 2 diabetes,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2015-01-41595,,NotApplicable,NotApplicable,2015,NotApplicable /,,No,Not Stated,"NotApplicable; Empagliflozin in combination therapy for treating type 2 diabetes, NotApplicable, ; NotApplicable():",QALY,"England, Wales",Diabetes mellitus,Pharmaceutical,canagliflozin vs. sitagliptin,Not Stated,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.50,3.50,4115,United Kingdom,2012,7699.25
32510,Empagliflozin in combination therapy for treating type 2 diabetes,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2015-01-41595,,NotApplicable,NotApplicable,2015,NotApplicable /,,No,Not Stated,"NotApplicable; Empagliflozin in combination therapy for treating type 2 diabetes, NotApplicable, ; NotApplicable():",QALY,"England, Wales",Diabetes mellitus,Pharmaceutical,empagliflozin vs. canagliflozin,Not Stated,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.50,3.50,-5722.22,United Kingdom,2012,-10706.4
32511,Empagliflozin in combination therapy for treating type 2 diabetes,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2015-01-41595,,NotApplicable,NotApplicable,2015,NotApplicable /,,No,Not Stated,"NotApplicable; Empagliflozin in combination therapy for treating type 2 diabetes, NotApplicable, ; NotApplicable():",QALY,"England, Wales",Diabetes mellitus,Pharmaceutical,canagliflozin vs. canagliflozin,Not Stated,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.50,3.50,10142.86,United Kingdom,2012,18977.5
32512,Empagliflozin in combination therapy for treating type 2 diabetes,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2015-01-41595,,NotApplicable,NotApplicable,2015,NotApplicable /,,No,Not Stated,"NotApplicable; Empagliflozin in combination therapy for treating type 2 diabetes, NotApplicable, ; NotApplicable():",QALY,"England, Wales",Diabetes mellitus,Pharmaceutical,empagliflozin vs. canagliflozin,Not Stated,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.50,3.50,-833.33,United Kingdom,2012,-1559.18
32513,Empagliflozin in combination therapy for treating type 2 diabetes,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2015-01-41595,,NotApplicable,NotApplicable,2015,NotApplicable /,,No,Not Stated,"NotApplicable; Empagliflozin in combination therapy for treating type 2 diabetes, NotApplicable, ; NotApplicable():",QALY,"England, Wales",Diabetes mellitus,Pharmaceutical,dapagliflozin vs. canagliflozin,Not Stated,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.50,3.50,Not Stated,United Kingdom,2012,Not Stated
32514,Empagliflozin in combination therapy for treating type 2 diabetes,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2015-01-41595,,NotApplicable,NotApplicable,2015,NotApplicable /,,No,Not Stated,"NotApplicable; Empagliflozin in combination therapy for treating type 2 diabetes, NotApplicable, ; NotApplicable():",QALY,"England, Wales",Diabetes mellitus,Pharmaceutical,empagliflozin vs. canagliflozin,Not Stated,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.50,3.50,-17545.45,United Kingdom,2012,-32827.92
32515,Empagliflozin in combination therapy for treating type 2 diabetes,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2015-01-41595,,NotApplicable,NotApplicable,2015,NotApplicable /,,No,Not Stated,"NotApplicable; Empagliflozin in combination therapy for treating type 2 diabetes, NotApplicable, ; NotApplicable():",QALY,"England, Wales",Diabetes mellitus,Pharmaceutical,empagliflozin vs. canagliflozin,Not Stated,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.50,3.50,-13818.18,United Kingdom,2012,-25854.12
32516,Empagliflozin in combination therapy for treating type 2 diabetes,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2015-01-41595,,NotApplicable,NotApplicable,2015,NotApplicable /,,No,Not Stated,"NotApplicable; Empagliflozin in combination therapy for treating type 2 diabetes, NotApplicable, ; NotApplicable():",QALY,"England, Wales",Diabetes mellitus,Pharmaceutical,sitagliptin vs. canagliflozin,Not Stated,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.50,3.50,-9676.47,United Kingdom,2012,-18104.89
32517,Empagliflozin in combination therapy for treating type 2 diabetes,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2015-01-41595,,NotApplicable,NotApplicable,2015,NotApplicable /,,No,Not Stated,"NotApplicable; Empagliflozin in combination therapy for treating type 2 diabetes, NotApplicable, ; NotApplicable():",QALY,"England, Wales",Diabetes mellitus,Pharmaceutical,canagliflozin vs. canagliflozin,Not Stated,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.50,3.50,9579,United Kingdom,2012,17922.52
32518,Vedolizumab for treating moderately to severely active ulcerative colitis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2015-01-41605,,NotApplicable,NotApplicable,2015,NotApplicable /,,No,Not Stated,"NotApplicable; Vedolizumab for treating moderately to severely active ulcerative colitis, NotApplicable, ; NotApplicable():",QALY,"England, Wales",Noninfective enteritis and colitis,Pharmaceutical,vedolizumab vs. conventional therapy,Not Stated,Not Stated,18 Years,"Male, Female",Full,10 Years,3.50,3.50,33297,United Kingdom,2013,60580.67
32519,Vedolizumab for treating moderately to severely active ulcerative colitis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2015-01-41605,,NotApplicable,NotApplicable,2015,NotApplicable /,,No,Not Stated,"NotApplicable; Vedolizumab for treating moderately to severely active ulcerative colitis, NotApplicable, ; NotApplicable():",QALY,"England, Wales",Noninfective enteritis and colitis,Pharmaceutical,vedolizumab vs. adalimumab,no prior TNF-alpha inhibitor,Not Stated,18 Years,"Male, Female",Full,10 Years,3.50,3.50,6634,United Kingdom,2013,12069.92
32520,Vedolizumab for treating moderately to severely active ulcerative colitis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2015-01-41605,,NotApplicable,NotApplicable,2015,NotApplicable /,,No,Not Stated,"NotApplicable; Vedolizumab for treating moderately to severely active ulcerative colitis, NotApplicable, ; NotApplicable():",QALY,"England, Wales",Noninfective enteritis and colitis,Pharmaceutical,vedolizumab vs. conventional therapy,no prior TNF-alpha inhibitor,Not Stated,18 Years,"Male, Female",Full,10 Years,3.50,3.50,4862,United Kingdom,2013,8845.94
32521,Vedolizumab for treating moderately to severely active ulcerative colitis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2015-01-41605,,NotApplicable,NotApplicable,2015,NotApplicable /,,No,Not Stated,"NotApplicable; Vedolizumab for treating moderately to severely active ulcerative colitis, NotApplicable, ; NotApplicable():",QALY,"England, Wales",Noninfective enteritis and colitis,Pharmaceutical,vedolizumab vs. surgery,prior TNF-alpha inhibitors failed,Not Stated,18 Years,"Male, Female",Full,10 Years,3.50,3.50,64999,United Kingdom,2013,118259.4
32522,Golimumab for ulcerative colitis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2014-01-41607,,NotApplicable,NotApplicable,2014,NotApplicable /,,No,Not Stated,"NotApplicable; Golimumab for ulcerative colitis, NotApplicable, ; NotApplicable():",QALY,Canada,Noninfective enteritis and colitis,Pharmaceutical,"golimumab vs. conventional therapy (oral corticosteroids, immunomodulators and/or oral 5-aminosalicylic acid compound)",nonresponsive to conventional therapy,Not Stated,18 Years,"Male, Female",Full,10 Years,3.00,3.00,43680,Canada,2013,49345.94
32523,Golimumab for ulcerative colitis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2014-01-41607,,NotApplicable,NotApplicable,2014,NotApplicable /,,No,Not Stated,"NotApplicable; Golimumab for ulcerative colitis, NotApplicable, ; NotApplicable():",QALY,Canada,Noninfective enteritis and colitis,Pharmaceutical,"golimumab vs. conventional therapy (oral corticosteroids, immunomodulators and/or oral 5-aminosalicylic acid compound)",nonresponsive to conventional therapy,Not Stated,18 Years,"Male, Female",Full,10 Years,3.00,3.00,43713,Canada,2013,49383.22
32524,Golimumab for ulcerative colitis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2014-01-41607,,NotApplicable,NotApplicable,2014,NotApplicable /,,No,Not Stated,"NotApplicable; Golimumab for ulcerative colitis, NotApplicable, ; NotApplicable():",QALY,Canada,Noninfective enteritis and colitis,Pharmaceutical,"adalimumab vs. conventional therapy (oral corticosteroids, immunomodulators and/or oral 5-aminosalicylic acid compound)",nonresponsive to conventional therapy,Not Stated,18 Years,"Male, Female",Full,10 Years,3.00,3.00,64775,Canada,2013,73177.27
32525,Golimumab for ulcerative colitis,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2014-01-41607,,NotApplicable,NotApplicable,2014,NotApplicable /,,No,Not Stated,"NotApplicable; Golimumab for ulcerative colitis, NotApplicable, ; NotApplicable():",QALY,Canada,Noninfective enteritis and colitis,Pharmaceutical,"infliximab vs. conventional therapy (oral corticosteroids, immunomodulators and/or oral 5-aminosalicylic acid compound)",nonresponsive to conventional therapy,Not Stated,18 Years,"Male, Female",Full,10 Years,3.00,3.00,73199,Canada,2013,82693.99
32526,"Apremilast for Psoriasis, moderate to severe plaque","NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2016-01-41608,,NotApplicable,NotApplicable,2016,NotApplicable /,,No,Not Stated,"NotApplicable; Apremilast for Psoriasis, moderate to severe plaque, NotApplicable, ; NotApplicable():",QALY,Canada,Papulosquamous disorders,Pharmaceutical,"apremilast vs. standard of care (topical agents, phototherapy and routine physician visits)",moderate-to-severe plaque psoriasis with inadequate response to prior conventional systemic therapies,Not Stated,18 Years,"Male, Female",Full,5 Years,5.00,5.00,105935,Canada,2014,109850.82
32527,"Apremilast for Psoriasis, moderate to severe plaque","NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2016-01-41608,,NotApplicable,NotApplicable,2016,NotApplicable /,,No,Not Stated,"NotApplicable; Apremilast for Psoriasis, moderate to severe plaque, NotApplicable, ; NotApplicable():",QALY,Canada,Papulosquamous disorders,Pharmaceutical,"adalimumab vs. standard of care (topical agents, phototherapy and routine physician visits)",moderate-to-severe plaque psoriasis with inadequate response to prior conventional systemic therapy,Not Stated,18 Years,"Male, Female",Full,5 Years,5.00,5.00,125136,Canada,2014,129761.57
32528,"Apremilast for Psoriasis, moderate to severe plaque","NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2016-01-41608,,NotApplicable,NotApplicable,2016,NotApplicable /,,No,Not Stated,"NotApplicable; Apremilast for Psoriasis, moderate to severe plaque, NotApplicable, ; NotApplicable():",QALY,Canada,Papulosquamous disorders,Pharmaceutical,etanercept vs. standard of care,moderate-to-severe plaque psoriasis with inadequate response to prior conventional systemic therapy,Not Stated,18 Years,"Male, Female",Full,5 Years,5.00,5.00,142518,Canada,2014,147786.08
32529,"Apremilast for Psoriasis, moderate to severe plaque","NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2016-01-41608,,NotApplicable,NotApplicable,2016,NotApplicable /,,No,Not Stated,"NotApplicable; Apremilast for Psoriasis, moderate to severe plaque, NotApplicable, ; NotApplicable():",QALY,Canada,Papulosquamous disorders,Pharmaceutical,"subsequent entry biologic infliximab vs. standard of care (topical agents, phototherapy and routine physician visits)",Not Stated,Not Stated,18 Years,"Male, Female",Full,5 Years,5.00,5.00,103762,Canada,2014,107597.49
32530,"Apremilast for Psoriasis, moderate to severe plaque","NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2016-01-41608,,NotApplicable,NotApplicable,2016,NotApplicable /,,No,Not Stated,"NotApplicable; Apremilast for Psoriasis, moderate to severe plaque, NotApplicable, ; NotApplicable():",QALY,Canada,Papulosquamous disorders,Pharmaceutical,ustekinumab vs. standard of care,moderate-to-severe plaque psoriasis with inadequate response to prior conventional systemic therapy,Not Stated,18 Years,"Male, Female",Full,5 Years,5.00,5.00,132062,Canada,2014,136943.58
32531,"Apremilast for Psoriasis, moderate to severe plaque","NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2016-01-41608,,NotApplicable,NotApplicable,2016,NotApplicable /,,No,Not Stated,"NotApplicable; Apremilast for Psoriasis, moderate to severe plaque, NotApplicable, ; NotApplicable():",QALY,Canada,Papulosquamous disorders,Pharmaceutical,secukinumab vs. standard of care,moderate-to-severe plaque psoriasis with inadequate response to prior conventional systemic therapy,Not Stated,18 Years,"Male, Female",Full,5 Years,5.00,5.00,125056,Canada,2014,129678.61
32532,"Apremilast for Psoriasis, moderate to severe plaque","NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2016-01-41608,,NotApplicable,NotApplicable,2016,NotApplicable /,,No,Not Stated,"NotApplicable; Apremilast for Psoriasis, moderate to severe plaque, NotApplicable, ; NotApplicable():",QALY,Canada,Papulosquamous disorders,Pharmaceutical,infliximab vs. standard of care,moderate-to-severe plaque psoriasis with inadequate response to prior conventional systemic therapy,Not Stated,18 Years,"Male, Female",Full,5 Years,5.00,5.00,198267,Canada,2014,205595.81
32533,"Apremilast for Psoriasis, moderate to severe plaque","NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2016-01-41608,,NotApplicable,NotApplicable,2016,NotApplicable /,,No,Not Stated,"NotApplicable; Apremilast for Psoriasis, moderate to severe plaque, NotApplicable, ; NotApplicable():",QALY,Canada,Papulosquamous disorders,Pharmaceutical,apremilast vs. standard of care,moderate-to-severe plaque psoriasis with inadequate response to prior conventional systemic therapy,Not Stated,18 Years,"Male, Female",Full,5 Years,5.00,5.00,188124,Canada,2014,195077.88
32543,Calcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2018-01-41559,,NotApplicable,NotApplicable,2018,NotApplicable /,,No,Not Stated,"NotApplicable; Calcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Episodic and paroxysmal disorders,Pharmaceutical,Erenumab vs. no intervention,chronic migraine,Not Stated,18 Years,"Male, Female",Full,2 Years,3.00,3.00,77214.29,United States,2017,85357.19
32544,Calcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2018-01-41559,,NotApplicable,NotApplicable,2018,NotApplicable /,,No,Not Stated,"NotApplicable; Calcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Episodic and paroxysmal disorders,Pharmaceutical,Fremanezumab vs. no intervention,chronic migraine,Not Stated,18 Years,"Male, Female",Full,2 Years,3.00,3.00,115000,United States,2017,127127.73
32545,Calcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2018-01-41559,,NotApplicable,NotApplicable,2018,NotApplicable /,,No,Not Stated,"NotApplicable; Calcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Episodic and paroxysmal disorders,Pharmaceutical,Erenumab vs. no intervention,episodic migraine,Not Stated,18 Years,"Male, Female",Full,2 Years,3.00,3.00,138125,United States,2017,152691.46
32546,Calcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2018-01-41559,,NotApplicable,NotApplicable,2018,NotApplicable /,,No,Not Stated,"NotApplicable; Calcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Episodic and paroxysmal disorders,Pharmaceutical,Fremanezumab vs. no intervention,episodic migraine,Not Stated,18 Years,"Male, Female",Full,2 Years,3.00,3.00,125100,United States,2017,138292.86
32547,Extended-Release Opioid Agonists and Antagonist Medications for Addiction Treatment (MAT) in Patients with Opioid Use Disorder: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2018-01-41576,,NotApplicable,NotApplicable,2018,NotApplicable /,,No,Not Stated,"NotApplicable; Extended-Release Opioid Agonists and Antagonist Medications for Addiction Treatment (MAT) in Patients with Opioid Use Disorder: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Mental and behavioural disorders due to psychoactive substance use,Pharmaceutical,extended-release injectable naltrexone (Vivitrol) vs. Generic sublingual (Buprenorphine or Naloxone),Not Stated,Not Stated,18 Years,"Male, Female",Full,5 Years,3.00,3.00,-343333.33,United States,2018,-370491.6
32548,Extended-Release Opioid Agonists and Antagonist Medications for Addiction Treatment (MAT) in Patients with Opioid Use Disorder: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2018-01-41576,,NotApplicable,NotApplicable,2018,NotApplicable /,,No,Not Stated,"NotApplicable; Extended-Release Opioid Agonists and Antagonist Medications for Addiction Treatment (MAT) in Patients with Opioid Use Disorder: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Mental and behavioural disorders due to psychoactive substance use,"Medical Device, Pharmaceutical, Surgical",buprenorphine subdermal implant (Probuphine) vs. Generic sublingual (Buprenorphine or Naloxone),Not Stated,Not Stated,18 Years,"Male, Female",Full,5 Years,3.00,3.00,265000,United States,2018,285961.96
32549,Antiandrogen Therapies for Nonmetastatic Castration-Resistant Prostate Cancer: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2018-01-41581,,NotApplicable,NotApplicable,2018,NotApplicable /,,No,Not Stated,"NotApplicable; Antiandrogen Therapies for Nonmetastatic Castration-Resistant Prostate Cancer: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Malignant neoplasms of male genital organs,Pharmaceutical,Apalutamide vs. standard of care: continued androgen deprivation therapy,rapidly rising prostate specific antigen,Not Stated,18 Years,Male,Full,Lifetime,3.00,3.00,68000,United States,2016,76772.59
32550,Antiandrogen Therapies for Nonmetastatic Castration-Resistant Prostate Cancer: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2018-01-41581,,NotApplicable,NotApplicable,2018,NotApplicable /,,No,Not Stated,"NotApplicable; Antiandrogen Therapies for Nonmetastatic Castration-Resistant Prostate Cancer: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Malignant neoplasms of male genital organs,Pharmaceutical,Enzalutamide vs. standard of care: continued androgen deprivation therapy,rapidly rising prostate specific antigen,Not Stated,18 Years,Male,Full,Lifetime,3.00,3.00,84000,United States,2016,94836.73
32551,Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41565,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Demyelinating diseases of the central nervous system,Pharmaceutical,Siponimod vs. best supportive care for multiple sclerosis,non-active secondary-progressive multiple sclerosis,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,1150000,United States,2017,1271277.33
32552,Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41565,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Demyelinating diseases of the central nervous system,Pharmaceutical,Siponimod vs. best supportive care for multiple sclerosis,active secondary progressive multiple sclerosis,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,433000,United States,2017,478663.55
32553,Oral Immunotherapy and Viaskin® Peanut for Peanut Allergy: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41568,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Oral Immunotherapy and Viaskin® Peanut for Peanut Allergy: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Persons with potential health hazards related to family and personal history and certain conditions influencing health status,Health Education or Behavior,AR101 oral immunotherapy vs. peanut avoidance due to allergy,Not Stated,17 Years,4 Years,"Male, Female",Full,Lifetime,3.00,3.00,88000,United States,2017,97280.35
32554,Oral Immunotherapy and Viaskin® Peanut for Peanut Allergy: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41568,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Oral Immunotherapy and Viaskin® Peanut for Peanut Allergy: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Persons with potential health hazards related to family and personal history and certain conditions influencing health status,"Health Education or Behavior, Pharmaceutical",Viaskin Peanut vs. peanut avoidance due to allergy,Not Stated,17 Years,4 Years,"Male, Female",Full,Lifetime,3.00,3.00,216000,United States,2017,238779.05
32555,"Deflazacort, Eteplirsen, and Golodirsen for Duchenne Muscular Dystrophy: Effectiveness and Value","NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41571,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Deflazacort, Eteplirsen, and Golodirsen for Duchenne Muscular Dystrophy: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Diseases of myoneural junction and muscle,Other,Deflazacort vs. Prednisone (generic) administered orally,Not Stated,Not Stated,5 Years,"Male, Female",Full,Lifetime,3.00,3.00,361000,United States,2017,399070.54
32556,"Deflazacort, Eteplirsen, and Golodirsen for Duchenne Muscular Dystrophy: Effectiveness and Value","NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41571,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Deflazacort, Eteplirsen, and Golodirsen for Duchenne Muscular Dystrophy: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Diseases of myoneural junction and muscle,Other,Deflazacort vs. Prednisone (generic) administered orally,Not Stated,Not Stated,5 Years,"Male, Female",Full,Lifetime,3.00,3.00,390000,United States,2017,431128.83
32557,Additive Therapies for Cardiovascular Disease: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41577,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Additive Therapies for Cardiovascular Disease: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Other forms of heart disease,Pharmaceutical,rivaroxaban vs. optimal medical management including aspirin (acetylsalicylic acid) for cardiovascular disease,treated with optimal medical management,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,36000,United States,2019,38156.28
32558,Additive Therapies for Cardiovascular Disease: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41577,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Additive Therapies for Cardiovascular Disease: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Ischaemic heart diseases,Pharmaceutical,icosapent ethyl vs. optimal medical management including statin therapy for cardiovascular disease,"treated with optimal medical management, including statins, also included patients at high risk for cardiovascular events",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,18000,United States,2019,19078.14
32559,Esketamine for the Treatment of Treatment-Resistant Depression: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41560,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Esketamine for the Treatment of Treatment-Resistant Depression: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Mood [affective] disorders,Pharmaceutical,esketamine nasal spray vs. Background antidepressant for depression,"single episode or recurrent major depressive disorder, no psychotic features, treatment resistent depresseion",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,198000,United States,2017,218880.79
32560,Spinraza® and Zolgensma® for Spinal Muscular Atrophy: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41578,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Spinraza® and Zolgensma® for Spinal Muscular Atrophy: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Systemic atrophies primarily affecting the central nervous system,Pharmaceutical,nusinersen vs. best supportive care,"type I spinal muscular atrophy, infantile-onset",6 Months,Not Stated,"Male, Female",Full,Lifetime,3.00,3.00,1112000,United States,2017,1229269.91
32561,Spinraza® and Zolgensma® for Spinal Muscular Atrophy: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41578,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Spinraza® and Zolgensma® for Spinal Muscular Atrophy: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Systemic atrophies primarily affecting the central nervous system,Pharmaceutical,onasemnogene abeparvovec vs. best supportive care,"type 1 spinal muscular atrophy, infantile-onset",6 Months,Not Stated,"Male, Female",Full,Lifetime,3.00,3.00,243000,United States,2017,268626.43
32562,Spinraza® and Zolgensma® for Spinal Muscular Atrophy: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41578,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Spinraza® and Zolgensma® for Spinal Muscular Atrophy: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Systemic atrophies primarily affecting the central nervous system,Pharmaceutical,nusinersin vs. best supportive care,"type II spinal muscular atrophy, type III spinal muscular atrophy",216 Months,18 Months,"Male, Female",Full,Lifetime,3.00,3.00,8156000,United States,2017,9016119.94
32563,Spinraza® and Zolgensma® for Spinal Muscular Atrophy: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2019-01-41578,,NotApplicable,NotApplicable,2019,NotApplicable /,,No,Not Stated,"NotApplicable; Spinraza® and Zolgensma® for Spinal Muscular Atrophy: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Systemic atrophies primarily affecting the central nervous system,Pharmaceutical,nusinersen vs. best supportive care,presymptomatic,18 Years,Not Stated,"Male, Female",Full,Lifetime,3.00,3.00,709000,United States,2017,783770.11
32564,Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41567,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Noninfective enteritis and colitis,Pharmaceutical,adalimumab vs. conventional treatment,biologic naive,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,1870000,United States,2019,1982006.75
32565,Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41567,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Noninfective enteritis and colitis,Pharmaceutical,golimumab vs. conventional treatment,biologic naive,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,1455000,United States,2019,1542149.64
32566,Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41567,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Noninfective enteritis and colitis,Pharmaceutical,infliximab vs. conventional treatment,biologic naive,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,212000,United States,2019,224698.09
32567,Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41567,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Noninfective enteritis and colitis,Pharmaceutical,infliximab-dyyb vs. conventional treatment,biologic niave,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,186000,United States,2019,197140.78
32568,Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41567,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Noninfective enteritis and colitis,Pharmaceutical,infliximab-abda vs. conventional treatment,biologic naive,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,195000,United States,2019,206679.85
32569,Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41567,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Noninfective enteritis and colitis,Pharmaceutical,ustekinumab vs. conventional treatment,biologic naive,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,1163000,United States,2019,1232659.81
32570,Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41567,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Noninfective enteritis and colitis,Pharmaceutical,vedolizumab vs. conventional treatment,biologic naive,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,887000,United States,2019,940128.34
32571,Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41567,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Noninfective enteritis and colitis,Pharmaceutical,adalimumab vs. infliximab,biologic naive,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,-541666.67,United States,2019,-574110.69
32572,Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41567,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Noninfective enteritis and colitis,Pharmaceutical,golimumab vs. infliximab,biologic naive,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,-522727.27,United States,2019,-554036.89
32573,Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41567,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Noninfective enteritis and colitis,Pharmaceutical,infliximab-dyyb vs. infliximab,biologic naive,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,Not Stated,United States,2019,Not Stated
32574,Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41567,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Noninfective enteritis and colitis,Pharmaceutical,infliximab-abda vs. infliximab,biologic naive,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,Not Stated,United States,2019,Not Stated
32575,Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41567,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Noninfective enteritis and colitis,Pharmaceutical,ustekinumab vs. infliximab,biologic naive,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,2960000,United States,2019,3137294.11
32576,Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41567,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Noninfective enteritis and colitis,Pharmaceutical,vedolizumab vs. infliximab,biologic naive,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,-15000000,United States,2019,-15898449.88
32577,Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41567,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Noninfective enteritis and colitis,Pharmaceutical,adalimumab vs. conventional treatment,biologic experienced,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,1885000,United States,2019,1997905.2
32578,Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41567,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Noninfective enteritis and colitis,Pharmaceutical,tofacitinib vs. conventional treatment,biologic experienced,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,495000,United States,2019,524648.85
32579,Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41567,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Noninfective enteritis and colitis,Pharmaceutical,ustekinumab vs. conventional treatment,biologic experienced,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,1252000,United States,2019,1326990.62
32580,Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41567,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Noninfective enteritis and colitis,Pharmaceutical,vedolizumab vs. conventional treatment,biologic experienced,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,902000,United States,2019,956026.79
32581,Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41567,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Noninfective enteritis and colitis,Pharmaceutical,tofacitinib vs. adalimumab,biologic experienced,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,-142857.14,United States,2019,-151413.81
32582,Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41567,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Noninfective enteritis and colitis,Pharmaceutical,ustekinumab vs. adalimumab,biologic experienced,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,996000,United States,2019,1055657.07
32583,Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41567,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Targeted Immune Modulators for Ulcerative Colitis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Noninfective enteritis and colitis,Pharmaceutical,vedolizumab vs. adalimumab,biologic experienced,Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,464000,United States,2019,491792.05
32584,Valoctocogene Roxaparvovec and Emicizumab for Hemophilia A without Inhibitors: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41570,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Valoctocogene Roxaparvovec and Emicizumab for Hemophilia A without Inhibitors: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,"Coagulation defects, purpura and other haemorrhagic conditions",Pharmaceutical,valoctocogene roxaparvovec vs. factor viii,"without inhibitors for factor VIII, require prophylaxis, severe hemophelia",Not Stated,18 Years,Male,Full,Lifetime,3.00,3.00,-1257250000,United States,2018,-1356700659.48
32585,Valoctocogene Roxaparvovec and Emicizumab for Hemophilia A without Inhibitors: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41570,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Valoctocogene Roxaparvovec and Emicizumab for Hemophilia A without Inhibitors: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,"Coagulation defects, purpura and other haemorrhagic conditions",Pharmaceutical,emicizumab vs. factor VIII,"without inhibitors for factor VIII, require prophylaxis",Not Stated,1 Years,Male,Full,Lifetime,3.00,3.00,Not Stated,United States,2018,Not Stated
32586,Modulator Treatments for Cystic Fibrosis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41580,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Modulator Treatments for Cystic Fibrosis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Metabolic disorders,Other,ivacaftor vs. best supportive care,eligible for ivacaftor monotherapy only,Not Stated,6 Months,"Male, Female",Full,Lifetime,3.00,3.00,1370000,United States,2019,1452058.42
32587,Modulator Treatments for Cystic Fibrosis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41580,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Modulator Treatments for Cystic Fibrosis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Metabolic disorders,Other,lumacaftor + ivacaftor vs. best supportive care,homozygous for F508del mutation,Not Stated,2 Years,"Male, Female",Full,Lifetime,3.00,3.00,1480000,United States,2019,1568647.05
32588,Modulator Treatments for Cystic Fibrosis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41580,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Modulator Treatments for Cystic Fibrosis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Metabolic disorders,Other,lumacaftor + ivacaftor vs. best supportive care,homozygous for F508del mutation,Not Stated,2 Years,"Male, Female",Full,Lifetime,3.00,3.00,1380000,United States,2019,1462657.39
32589,Modulator Treatments for Cystic Fibrosis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41580,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Modulator Treatments for Cystic Fibrosis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Metabolic disorders,Other,lumacaftor/ivacaftor vs. best supportive care,homozygous for F508del mutation,Not Stated,2 Years,"Male, Female",Full,Lifetime,3.00,3.00,1160000,United States,2019,1229480.12
32590,Modulator Treatments for Cystic Fibrosis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41580,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Modulator Treatments for Cystic Fibrosis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Other nutritional deficiencies,Other,ivacaftor vs. best supportive care,"heterozygous F508del, residual function mutation",Not Stated,6 Months,"Male, Female",Full,Lifetime,3.00,3.00,1340000,United States,2019,1420261.52
32591,Modulator Treatments for Cystic Fibrosis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41580,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Modulator Treatments for Cystic Fibrosis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Metabolic disorders,Other,ivacaftor vs. best supportive care,"heterozygous F508del mutation, residual function mutation",Not Stated,6 Months,"Male, Female",Full,Lifetime,3.00,3.00,1100000,United States,2019,1165886.32
32592,Modulator Treatments for Cystic Fibrosis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2020-01-41580,,NotApplicable,NotApplicable,2020,NotApplicable /,,No,Not Stated,"NotApplicable; Modulator Treatments for Cystic Fibrosis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Metabolic disorders,Other,elexacaftor + tezacaftor + ivacaftor vs. best supportive care,"heterozygous F508del, minimal function mutation",Not Stated,12 Years,"Male, Female",Full,Lifetime,3.00,3.00,1050000,United States,2019,1112891.49
32593,Aducanumab for Alzheimer’s Disease: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2021-01-41562,,NotApplicable,NotApplicable,2021,NotApplicable /,,No,Not Stated,"NotApplicable; Aducanumab for Alzheimer’s Disease: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Other degenerative diseases of the nervous system,Pharmaceutical,aducanumab vs. supportive care,"mild Alzheimer's disease, mild cognitive impairment due to Alzheimer's disease",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,1330000,United States,2020,1392483.7
32594,Aducanumab for Alzheimer’s Disease: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2021-01-41562,,NotApplicable,NotApplicable,2021,NotApplicable /,,No,Not Stated,"NotApplicable; Aducanumab for Alzheimer’s Disease: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Other degenerative diseases of the nervous system,Pharmaceutical,aducanumab vs. supportive care,"mild cognitive impairment from Alzheimer's disease, mild Alzheimer's disease",Not Stated,18 Years,"Male, Female",Full,Lifetime,3.00,3.00,1270000,United States,2020,1329664.89
32595,Bempedoic Acid and Inclisiran for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2021-01-41563,,NotApplicable,NotApplicable,2021,NotApplicable /,,No,Not Stated,"NotApplicable; Bempedoic Acid and Inclisiran for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Ischaemic heart diseases,Pharmaceutical,bempedoic acid + ezetimibe vs. ezetimibe,Not Stated,Not Stated,35 Years,"Male, Female",Full,Lifetime,3.00,3.00,186000,United States,2020,194738.32
32596,Bempedoic Acid and Inclisiran for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2021-01-41563,,NotApplicable,NotApplicable,2021,NotApplicable /,,No,Not Stated,"NotApplicable; Bempedoic Acid and Inclisiran for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Ischaemic heart diseases,Pharmaceutical,inclisiran vs. ezetimibe,Not Stated,Not Stated,35 Years,"Male, Female",Full,Lifetime,3.00,3.00,157000,United States,2020,164375.9
32597,Bempedoic Acid and Inclisiran for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2021-01-41563,,NotApplicable,NotApplicable,2021,NotApplicable /,,No,Not Stated,"NotApplicable; Bempedoic Acid and Inclisiran for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,"Ischaemic heart diseases, Metabolic disorders",Pharmaceutical,bempedoic acid + ezetimibe vs. ezetimibe,Not Stated,Not Stated,35 Years,"Male, Female",Full,Lifetime,3.00,3.00,101000,United States,2020,105745
32598,Bempedoic Acid and Inclisiran for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2021-01-41563,,NotApplicable,NotApplicable,2021,NotApplicable /,,No,Not Stated,"NotApplicable; Bempedoic Acid and Inclisiran for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,"Ischaemic heart diseases, Metabolic disorders",Pharmaceutical,inclisiran vs. ezetimibe,Not Stated,Not Stated,35 Years,"Male, Female",Full,Lifetime,3.00,3.00,84000,United States,2020,87946.34
32599,Belimumab and Voclosporin for Lupus Nephritis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2021-01-41575,,NotApplicable,NotApplicable,2021,NotApplicable /,,No,Not Stated,"NotApplicable; Belimumab and Voclosporin for Lupus Nephritis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Systemic connective tissue disorders,Pharmaceutical,belimumab vs. standard of care,Not Stated,Not Stated,18 Years,"Male, Female",Full,Lifetime,Not Stated,Not Stated,89663,United States,2019,95033.51
32600,Belimumab and Voclosporin for Lupus Nephritis: Effectiveness and Value,"NOTE FROM THE CEA REGISTRY TEAM: While peer-reviewed literature is the primary focus of CEVR’s data collection strategy, we completed a pilot project to capture reports from health technology assessment (HTA) agencies in 2022. Our project collected data from a random sample of HTA reports published by the National Institute for Health and Care Excellence (NICE); the Canadian Agency for Drugs and Technologies in Health (CADTH); the U.S.-based Institute for Clinical and Economic Review (ICER); Instituto de Evaluación Tecnológica en Salud (IETS) in Colombia; and Brazil’s Comissão Nacional de Incorporação de Tecnologias no Sus (CONITEC). Data for this cost-effectiveness analysis were retrieved from an HTA report as part of the pilot project. For more information on this pilot project, please contact cea@tuftsemedicalcenter.org.",2021-01-41575,,NotApplicable,NotApplicable,2021,NotApplicable /,,No,Not Stated,"NotApplicable; Belimumab and Voclosporin for Lupus Nephritis: Effectiveness and Value, NotApplicable, ; NotApplicable():",QALY,United States of America,Systemic connective tissue disorders,Pharmaceutical,voclosporin vs. standard care,Not Stated,Not Stated,18 Years,"Male, Female",Full,Lifetime,Not Stated,Not Stated,149260,United States,2019,158200.18
